MP
NKTR icon

Mangrove Partners’s Nektar Therapeutics NKTR Stock Holding History

Mangrove Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$220K Buy
+3,057
New +$174K 0.02% 338

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mangrove Partners's NKTR Position: Q1 2026 in Review

Mangrove Partners opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 3,057 shares worth $220K. The stake represents 0.02% of the portfolio and ranks #338 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Mangrove Partners held 3,057 shares of Nektar Therapeutics worth $220K as of Q1 2026.
  • Nektar Therapeutics was a new Mangrove Partners position in Q1 2026.
  • Nektar Therapeutics made up 0.02% of Mangrove Partners's portfolio in Q1 2026, its #338 holding.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.